A NGIOTENSIN II (Ang II) participates in the control of blood pressure, cardiac contractility, regulation of regional blood flow, and cellular growth and repair (1, 2) . This hormone specifically activates at least two well characterized transmembrane G protein-coupled receptors belonging to the seven-transmembrane-spanning receptor family, namely, angiotensin receptor 1 (AT1) and angiotensin receptor 2 (AT2) (3, 4) . At least four intracellular pathways participate in transduction of the Ang II signal in target cells. Activation of G protein G q leads to inositol 1,4,5-triphosphate generation and a subsequent rise in cytosolic free calcium, which modulates cell contractility, vesicular trafficking, gene transcription, and mitogenesis (5, 6) ; on the other hand, induction of G protein G i inhibits cAMP (7) . The third mechanism involves the activation of extracellular signal-regulated kinase (ERK) cascade (8) , and the fourth mechanism leads to activation of Janus kinase 2 (JAK2), an intracellular kinase commonly engaged by receptors belonging to class I and class II cytokine families, which rapidly directs the signal toward the nucleus through the signal transducer and activator of transcription (STAT) proteins (9, 10) .
Several intracellular signaling systems that use the JAK/ STAT pathway to transduce their message are controlled by members of the suppressor of cytokine signaling (SOCS) family (11, 12) . SOCS proteins are under the transcriptional control of STATs (13, 14) , and once induced, target receptor/ JAK complexes through a central Src homology 2 domain and a C-terminal SOCS box domain (15, 16) . In IL-6 signaling, SOCS3 transcripts are detected as early as 30 min after IL-6 treatment of cultured cells (17) . The translated SOCS3 then migrates and interacts with Tyr 759 in the IL-6 receptor subunit gp130, thereby inhibiting further activation of the IL-6/JAK2/STAT signaling pathway (17) . Thus, in addition to the already known intracellular systems that participate in the control of hormone, growth factor, and cytokine signaling, including tyrosine phosphatases, serine-threonine kinases, and protein inhibitor of activated STATs, the SOCS family causes a medium-to long-term inhibition and refractoriness of signaling pathways that engage JAKs and STATs (18, 19) .
As Ang II activates JAK2 and STAT-1, -2, -3, and -5, we have investigated the possible involvement of SOCS3 in Ang II-mediated physiological events in rat heart and neonatal rat ventricular myocytes (NRVM). RT-PCR, immunoprecipitation, Western blotting, and immunohistochemistry studies reveal that rat heart and NRVM constitutively express low level of SOCS3, which is rapidly induced by Ang II infusion. The blockade of SOCS3 expression leads to a loss of desensitization of Ang II signaling. Thus, SOCS3 modulates Ang II signaling in heart and NRVM.
Materials and Methods

Antibodies and chemicals
Pharmacia Biotech (Uppsala, Sweden), [ 125 I]protein A, and nitrocellulose membranes were obtained from Amersham Pharmacia Biotech (Little Chalfont, UK). Antibodies against AT1 (rabbit polyclonal, sc-579), JAK2 (rabbit polyclonal, sc-278 and sc-7229), phosphotyrosine (pY; mouse monoclonal, sc-508), c-Jun (rabbit polyclonal, sc-1694), phospho-STAT1 (Tyr 701 , goat polyclonal, sc-7988), phospho-ERK (pERK, Tyr 204 mouse monoclonal, sc-7383, recognizes ERK, 44 and 42 kDa) and SOCS3 (rabbit polyclonal, sc-9023 and goat polyclonal, sc-7009) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The secondary antibodies and conjugates used in immunohistochemistry were obtained from Vector Laboratories, Inc. (Burlingame, CA). Chemicals, culture media, Lipofectamine Plus, and sera used in myocyte preparation and culture were purchased from Life Technologies, Inc. Chemicals employed in RT-PCR experiments, primers for SOCS3 (sense, 5Ј-ACC TCT CTC CTC CAA CG-3Ј; antisense, 5Ј-TGC TGG GCT AAC TGG-3Ј), ␤-actin (sense, 5Ј-TTT GGG AGG GTG AGG GAC TTC-3Ј; antisense, 5Ј-TGA GCG CAA GTA CTC TGT GTG G-3Ј), and phosphorthioatemodified oligodeoxynucleotides for SOCS3 (sense, 5Ј-CAT GGT CAC CCA CAG-3Ј; antisense, 5Ј-CTG TGG GTG ACC ATG-3Ј; scrambled, 5Ј-GCT AGC GAT GTC TGG-3Ј), were synthesized by Life Technologies, Inc. Sodium amobarbital was obtained from Eli Lilly & Co. (Indianapolis, IN).
Animals
Male Wistar rats (1-3 d old for cardiomyocyte preparation or 48 d old/150 -200 g for the remaining experiments) from the University's Central Animal Breeding Center were used in the experiments. The adult rats were allowed access to standard rodent chow and water ad libitum. Food was withdrawn 12 h before the experiments. Rats were anesthetized by an ip injection of sodium amobarbital (15 mg/kg body weight), and the experiments were initiated after the loss of corneal and pedal reflexes. All experiments were conducted in accord with the principles and procedures described by NIH Guidelines for the Care and Use of Experimental Animals and were approved by the State University of Campinas ethical committee.
Preparation of NRVM
Ventricular cardiac myocytes were prepared by enzymatic disaggregation as described previously (20) . Hearts from neonatal (1-3 d old) Wistar rats were excised, and the ventricles were minced and suspended in sterile ADS buffer [4.36 g HEPES, free acid (pH 7.35), 6.8 g NaCl, 1.0 g d-glucose, 0.4 g KCl, 0.14 g NaH 2 PO 4 ⅐H 2 O, 0.1 g MgSO 4 -anhydrous, and 0.02 g phenol red]. Tissue was then subjected to multiple enzymatic digestions at 37 C using a mixture of collagenase and pancreatin. Four or five successive digestions were performed, each lasting 20 min. The solution obtained during each digestion was transferred to a sterile tube containing 1.0 ml newborn calf serum and centrifuged. The pellets obtained were resuspended in newborn calf serum. To separate myocytes from other cells, the suspension was layered onto a discontinuous Percoll density gradient consisting of two phases. After washing to remove traces of Percoll, the myocytes were cultured in DMEM containing 5% fetal calf serum, 10% horse serum, and 100 U penicillinstreptomycin/ml. The cells were plated at the concentration of 6.0 ϫ 10 4 /cm 2 on plates previously coated with 0.1% gelatin. The purity of the preparation was ascertained by immunofluorescence using TRITCphaloidin and evaluation by confocal microscopy.
Ang II treatment and tissue extraction
The abdominal cavity was opened, the vena cava was exposed, and 0.02 ml saline (0.9% NaCl), with or without 10 Ϫ6 m Ang II (or concentrations ranging from 10
Ϫ12
-10
Ϫ6 m in dose-response experiments), was injected. Some rats received losartan (10 mg/kg, ip) 30 min before the experiments. In some cases rats received 6.0 nmol (diluted in 200 l TE buffer) sense, antisense, or scrambled SOCS3 oligonucleotide 3 h before the experiments. Based on the Rattus norvegicus SOCS3 mRNA sequence (accession no. AF075383 at NCBI Entrez Nucleotide), three different sequences were designed and tested by ip injection of 6.0 nmol antisense or respective sense oligonucleotide, and they were evaluated for their ability to block SOCS3 synthesis by measuring SOCS3 in immunoprecipitation experiments of heart protein extracts. The sequence 5Ј-CTG TGG GTG ACC ATG-3Ј was capable of reducing 80% (P Ͻ 0.05) Ang II-stimulated SOCS3 expression and was used in all experiments in parallel with its respective sense sequence as control. At various time intervals (as shown in Results), the tips of the ventricles were excised and immediately homogenized in approximately 5 vol solubilization buffer at 4 C [1% Triton X-100, 100 mm Tris-HCl (pH 7.4), 100 mm sodium pyrophosphate, 100 mm sodium fluoride, 10 mm EDTA, 10 mm sodium vanadate, 2.0 mm phenylmethylsulfonylfluoride, and 0.1 mg aprotinin/ ml] with a Polytron PTA 20S generator (model PT 10/35; Brinkmann Instruments, Westbury, NY) operated at maximum speed for 30 sec.
Cardiomyocytes plated at a density of 6.0 ϫ 10 4 /cm 2 were exposed to Ang II (doses and time as stated in Results and figures) and losartan (10 Ϫ5 m, loaded 30 min before the experiment). In some experiments cells were treated with neomycin (800 g/ml) during the same period of treatment with Ang II. For treatment with sense, antisense, or scrambled SOCS3 oligonucleotides, NRVM were plated (6.0 ϫ 10 4 /cm 2 ), washed in serum-and antibiotic-free DMEM, and maintained in this medium for 3 h. Sense, antisense, or scrambled oligonucleotides were added to the culture medium (1.0 m) in parallel with the transfection reagent Lipofectamine Plus (10 g/ml). After 8 h, the medium was replaced with 20% fetal calf serum/DMEM and incubated overnight. The next day, the cells were exposed to Ang II and losartan. After stimulation, the cells were washed twice in ice-cold PBS and scraped into ice-cold solubilization buffer (as for heart extraction).
Protein analyses by immunoblotting
Insoluble material was removed by centrifugation for 25 min at 11,000 rpm in a 70.Ti rotor (Beckman, Fullerton, CA) at 4 C. The protein concentration of the supernatants was determined with the Bradford dye-binding method (21) . Aliquots of the resulting supernatants containing 5.0 mg total protein were used for immunoprecipitation with anti-AT1, anti-JAK2, anti-pY, or anti-SOCS3 antibodies at 4 C overnight, followed by the addition of protein A-Sepharose 6MB for 2 h. The pellets were washed three times in ice-cold buffer [0.5% Triton X-100, 100 mm Tris (pH 7.4), 10 mm EDTA, and 2.0 mm sodium vanadate]. After washing, the pellet was resuspended in Laemmli's sample buffer (22) containing 100 mm dithiothreitol and heated in a boiling water bath for 5 min. The samples were subjected to SDS-PAGE (10%, 12%, or 15% bis-acrylamide) in a Bio-Rad miniature slab gel apparatus (Bio-Rad Laboratories). Electrotransfer of proteins from the gel to the nitrocellulose membrane was performed for 90 min at 120 V (constant) in a Bio-Rad miniature transfer apparatus (Mini-Protean) as described by Towbin et al. (23) . The nitrocellulose membranes were preincubated in blocking buffer (5% BSA, 10 mm Tris, 150 mm NaCl, and 0.02% Tween 20) for 2 h. The nitrocellulose blot was then incubated with the appropriate antibody diluted in blocking buffer (3% BSA instead of nonfat dry milk) overnight at 4 C and washed for 15 min with the blocking buffer without BSA. The blots were subsequently incubated with 2.0 mCi [ 125 I]protein A in 10 ml blocking buffer for 2 h at room temperature and washed again as described above for 15 min. [
125 I]Protein A bound to the antibodies was detected by autoradiography using preflashed Kodak XAR film with Cronex Lightning Plus intensifying screens (Eastman Kodak, Rochester, NY) at Ϫ70 C for 24 -72 h. Band intensities were quantified by digital densitometry (Scion Image software, Scion Corp., Frederick, MD) of the developed autoradiographs. For simple immunoblot experiments (not preceded by immunoprecipitation), 0.2 mg total protein from heart or cardiomyocyte extracts was separated by SDS-PAGE (10%, 12%, or 15% bis-acrylamide), transferred to nitrocellulose membranes, and blotted with the appropriate antibodies (anti-pY, antiphospho-STAT1, anti-phospho-ERK, anti-SOCS3, anti-JAK2, or anti-cJun) (24, 25) .
Immunohistochemistry
Rat hearts were fixed in buffered 4% paraformaldehyde in 0.2 m PBS (pH 7.4) for 24 h and embedded in paraffin, and 3.0-msections were obtained. The glass-mounted sections were cleared of paraffin with xylene and rehydrated by sequential washings with graded ethanol solutions (70 -100%). After permeabilization with 0.1% Triton X-100 in PBS (pH 7.4) for 10 min at room temperature, the sections were incubated in 1% H 2 O 2 in PBS for 30 min to quench the endogenous peroxidase activity. The sections were pretreated in a microwave oven in sodium citrate buffer (pH 7.4) for 10 min. After washing in PBS, the sections were blocked with 3% nonfat dry milk in PBS for 1 h at 37 C, followed by overnight incubation with the primary antibody (anti-SOCS3 rabbit polyclonal, 1:20 dilution; anti-AT1 rabbit polyclonal, 1:20) in 1% BSA in PBS at 4 C in a moist chamber. The sections were subsequently washed and incubated with a specific biotinylated antirabbit secondary antibody (Vector Laboratories, Inc., Burlingame, CA; 1:150 dilution) for 2 h at room temperature, followed by incubation with streptavidin reagent containing avidin-conjugated peroxidase. The color reaction was developed using a diaminobenzidene substrate kit (Vector Laboratories) according to the manufacturer's recommendations. After the color reaction, the sections were counterstained with Harris hematoxylin, dehydrated through an ethanol series into xylene, and mounted using Entelan mounting media (Microscopy, Karlsruhe, Germany). Secondary antibody specificity was tested in a series of positive and negative controls. In the absence of primary antibodies, incubation with secondary antibodies (negative controls) failed to produce any significant staining. The images were obtained using an optical microscope (Leica, Wetzlar, Germany) and were acquired with a Focus Imagecorder Plus System (26) .
RNA isolation
Rat heart ventricles were excised and rapidly frozen in liquid nitrogen. Total RNA was extracted from whole ventricles using TRIzol reagent (Life Technologies, Inc.), according to the manufacturer's recommendations. Total RNA was quantified by spectrophotometry at A260 nm, and its integrity was determined from the A260/A280 nm ratio. After 24 h, isolated total RNA was rendered genomic DNA-free by digestion with ribonuclease-free deoxyribonuclease (RQ1; Promega Corp., Madison, WI).
Semiquantitative RT-PCR
RT-PCR was used to determine the mRNA expression of SOCS3, measuring ␤-actin as an internal standard. Seven micrograms of total RNA from each heart were reverse transcribed with SuperScript reverse transcriptase (200 U/l) using oligo(deoxythymidine) (50 mm) in a 30-l reaction volume (5ϫ RT buffer, 10 mm deoxy-NTP, and 40 U/l ribonuclease-free inhibitor). The RTs involved a 50-min incubation at 42 C and a 15-min incubation at 70 C. After RT, 0.75 l of the RT product was used in each PCR to a final volume of 50 l (10ϫ PCR buffer, 1.0 mm deoxy-NTP, 50 mm MgCl 2 , Taq polymerase, and sense and antisense primers for SOCS3 and ␤-actin). The expression of mRNA was determined by PCR using the primers described in Antibodies and chemicals, and amplified a 251-bp DNA fragment of SOCS3 and a 489-bp DNA fragment of ␤-actin. Triplicate reactions were performed using an initial incubation at 94 C for 5 min, denaturation at 94 C for 1 min, followed by annealing at 52 C for 50 sec, extension at 72 C for 1 min, and a final extension at 72 C for 7 min. A cycle titration between 20 -40 cycles of RT-PCR products revealed that 23 cycles for ␤-actin and 30 cycles for SOCS3 were within the logarithmic phase of amplification. Therefore, those PCR conditions were used in subsequent experiments. All PCR experiments included a control tube with no RT step. PCR-amplified products were run on 2% Tris/acetic acid/EDTA agarose gels, and the DNA was visualized by ethidium bromide staining. The molecular size of the products was determined using a 1-kb Plus DNA ladder (Life Technologies, Inc.) as standard size marker. Images of the bands were obtained using a TFX 35M UV transluminator (Life Technologies, Inc.), and band intensity was quantified by digital densitometry (Scion Image software).
Data presentation and statistical analysis
The results are expressed as the mean Ϯ sd of the indicated number of experiments, as appropriate. The blots are presented as direct comparisons of bands in autoradiographs and quantified by densitometry using Scion Image software. The t test for unpaired samples was used for statistical analysis. The level of significance was set at P Ͻ 0.05.
Results
Ang II induces SOCS3 protein expression in rat heart and isolated cardiomyocytes
To investigate Ang II-induced SOCS3 expression, rats received an intracava injection of 0.02 ml of a solution containing 10 Ϫ6 m Ang II and after 0 -360 min, the hearts were surgically removed and homogenized for protein expression analyses. As shown in Fig. 1A , SOCS3 (30 kDa), which was already present in heart at protein levels that approximated the detection limit of the method, was induced 10 min after treatment with Ang II and reached maximum expression at 120 min. Thereafter, the level of SOCS3 decreased and had returned to basal expression levels at 360 min. Evaluation of SOCS3 expression in nitrocellulose transfers of total protein extracts resolved by SDS-PAGE yielded no detectable bands. In the latter experiments, up to 0.25 mg total protein was loaded into each cell of the electrophoretic apparatus. Thus, even after stimulation with Ang II, the amount of SOCS3 in heart is below the detection limit of the method, and only after partial purification by immunoprecipitation can the protein be detected.
To investigate the dose-dependency of the SOCS3 response to Ang II, experiments were performed after the infusion of 0.02 ml saline or the same volume of saline containing 10 Ϫ12 , 10 Ϫ10 , 10 Ϫ8 , and 10 Ϫ6 m Ang II. Tissue specimens were obtained at 120 min, and heart homogenates were submitted to immunoprecipitation, separation by SDS-PAGE, transfer to nitrocellulose membranes, and evaluation of protein amounts by Western blot with specific antibodies. Enhanced SOCS3 expression was detected after treatment with 10 Ϫ8 m Ang II, which provides a serum concentration of Ang II within the physiological range (Fig. 1B) .
To examine whether Ang II exerted an effect on SOCS3 expression at the transcriptional level, total RNA extracted from hearts was reverse transcribed and amplified using specific primers for SOCS3 and ␤-actin. Before stimulation with Ang II, SOCS3 transcripts were already present at low levels in the heart. After stimulation with 10 Ϫ6 m Ang II, no early increase was detected (at 1.5 min), but at 60 min a 1.5-fold rise in SOCS3 mRNA was evident and differed significantly from basal levels (Fig. 1C) . At 360 min, SOCS3 transcripts had fallen to below basal levels. Thus, it seems that Ang II initially regulates SOCS3 expression at the translation level and only later affects the rate of transcription.
To exclude the possibility of an indirect in vivo effect of blood pressure fluctuations or participation of other hormonal systems on SOCS3 induction, isolated neonatal cardiomyocytes were treated with Ang II (10 Ϫ11 , 10 Ϫ9 , 10 Ϫ7 , and 10 Ϫ5 m) for 120 min. Protein extracts from these samples were evaluated by immunoprecipitation, SDS-PAGE, and immunoblotting with anti-SOCS3 antibodies. As depicted in Fig.  1D , Ang II was capable of inducing SOCS3 expression in NRVM beginning at 10 Ϫ7 m Ang II. The difference in sensitivity to Ang II between hearts of living rats and NRVM may occur because of age differences (living animals were adults, and NRVM were obtained from neonatal rats), as Ang II receptors are regulated during ontogeny (27) , or due to culture conditions that may affect AT1 expression and turnover (28) .
Tissue distribution of Ang II-induced SOCS3 expression in rat heart
To determine the histological distribution of SOCS3 in cardiac tissue of rats, sections were obtained from several subareas of Ang II-treated (10 Ϫ6 m, 120 min) and control hearts. Figure 2 , A-D, shows the pattern of basal (non-Ang II-stimulated) SOCS3 protein expression predominantly in the endocardium and in the endothelium and smooth muscle of the coronary arteries of left ventricle and atrium. After treatment with Ang II, a marked increase in the intensity of SOCS3 staining was detected in the same areas as those mentioned above (Fig. 2, E-H) . Therefore, it seems that Ang II stimulates an increase in SOCS3 expression in the same areas where it is present before hormone stimulation and does not promote its expression (at least at detectable amounts by this method) in muscle or other cells types present in the heart. Interestingly, the expression of SOCS3 coincides with regions that possess higher concentrations of AT1 receptors (Fig. 2, I -J).
Ang II induces the association of JAK2 and SOCS3 in rat heart and cardiomyocytes
To investigate the association of SOCS3 with JAK2 after Ang II treatment, heart protein homogenates from rats treated or not with 10 Ϫ6 m Ang II for different periods of time were immunoprecipitated with a polyclonal anti-SOCS3 antibody. The immunoprecipitates were then immunoblotted with a polyclonal antibody against JAK2. As shown in Fig.  3A , the anti-SOCS3 antibody coimmunoprecipitated small amounts of JAK2 (130 kDa) at time zero. However, 10 min after Ang II treatment, the amount of coprecipitating JAK2 increased significantly. The formation of complexes increased significantly and was maximal 120 min after Ang II treatment, remaining steady for at least 180 min and returning to near basal levels at 360 min. In additional experiments, anti-JAK2 immunoprecipitates were immunoblotted with anti-SOCS3 antibody, and a 30-kDa band (SOCS3) was detected (Fig. 3B) . In dose-response experiments, NRVM were exposed to Ang II for 120 min, and the SOCS3/JAK2 asso- Ϫ6 M Ang II was administered into the vena cava as a bolus injection. After the elapsed time indicated in the figure, the tips of left ventricles were excised and homogenized in solubilization buffer at 4 C, immunoprecipitated with rabbit anti-SOCS3 antibody (␣ SOCS3), and immunoblotted (IB) with goat anti-SOCS3 antibody. The inset depicts a whole blot of a typical run containing a sample from a control (0 min) and a sample from a 10 Ϫ6 M Ang II-treated rat (120 min; n ϭ 3; *, P Ͻ 0.05). B, Rats were anesthetized, the abdominal wall was incised, and 0.02 ml saline or Ang II at the concentrations indicated in the figure was injected. After 120 min, the tips of the left ventricles were excised and homogenized in solubilization buffer at 4 C, immunoprecipitated with rabbit anti-SOCS3 antibody, and immunoblotted with goat anti-SOCS3 antibody (n ϭ 3; *, P Ͻ 0.05). C, Rats were anesthetized, the abdominal wall was incised, and 0.02 ml 10 Ϫ6 M Ang II was administered into the vena cava as a bolus injection. After the elapsed time indicated in the figure, the tips of the left ventricles were excised and homogenized in TRIzol; RNA was reverse transcribed and PCR-amplified using SOCS3-specific primers. Products were separated in 2% agarose gel and stained with ethidium bromide. Upper part, The 489-bp ␤-actin as internal standard and the 251-bp SOCS3 PCR product. Lower part, Histogram of the quantification of SOCS3 mRNA (n ϭ 3; *, P Ͻ 0.05). D, NRVM were prepared following a technique described in the text and were plated in DMEM at a concentration of 6.0 ϫ 10 4 /cm 2 on plates previously coated with 0.1% gelatin. Ang II was applied to culture medium at concentrations depicted in the figure. After 120 min, cells were harvested, homogenized, and used for immunoprecipitation with rabbit anti-SOCS3 antibody. Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with goat anti-SOCS3 antibody. The inset depicts a whole blot of a typical run containing a sample from control (no Ang II) and a sample from cells treated with 10 Ϫ5 M Ang II (n ϭ 3; *, P Ͻ 0.05). AII, Ang II; MW, molecular mass standards in kilodaltons.
ciation was then assessed by immunoprecipitation (anti-SOCS3) and immunoblotting (anti-JAK2). As in heart tissue, NRVM responded to Ang II by exhibiting a dose-dependent association between SOCS3 and JAK2 (Fig. 3C ).
SOCS3 is induced by Ang II through AT1-dependent signaling in heart and cardiomyocytes
Heart and cardiomyocytes express both forms of Ang II receptors, AT1 and AT2. As AT1 is expressed at a higher concentration than AT2 in both tissues, and its preferential histological distribution in heart coincides with the sites of greater Ang II-induced SOCS3 expression, we performed a series of experiments using the specific AT1 blocker losartan to assess the Ang II receptor type involved in the induction of SOCS3 expression in both tissues. For that purpose, living rats or NVRM were treated with saline, losartan (10 mg/kg for rats or 10 Ϫ5 m in culture medium for cells), Ang II (0.02 ml of 10 Ϫ6 m for rats or 10 Ϫ7 m in culture medium for cells), or losartan (doses and concentrations as described above, given 30 min before Ang II), followed by Ang II (same doses and concentrations as described above). At the established times, protein extracts were obtained to assess AT1, JAK2, and STAT1 tyrosine phosphorylation (Fig. 3, D and E), SOCS3 expression (Fig. 3, D and E) , and JAK2/SOCS3 association (Fig. 3, F and G) . As depicted in the figures, losartan abolished Ang II-induced tyrosine phosphorylation of AT1, JAK2, and STAT1. Moreover, losartan inhibited the expression of SOCS3 (Fig. 3, D and E) and its association with JAK2 (Fig. 3, F and G) in heart and NVRM. Thus, the action of Ang II on the expression and engagement of SOCS3 occurs via a losartan-sensitive mechanism and shows the same pattern of activation of the JAK/STAT pathway induced by Ang II.
Fractional involvement of JAK2 in Ang II-induced JAK2 tyrosine phosphorylation and Ang II-induced SOCS3/JAK2 association
Members of the SOCS family participate in the physiological control of cytokine signal transduction by binding to JAKs and temporarily inhibiting further stimulation of the JAK/STAT pathway. Significant blockade presumably occurs when most of the JAK2 involved in an initial stimulating event is engaged by SOCS3 and therefore unavailable for further action. To investigate the relative participation of JAK2 in Ang II signaling and its engagement by SOCS3, immunodepletion experiments were performed using a surplus of antibody (5.0 g) against pY or SOCS3 and running SDS-PAGEs of the starting protein extracts in parallel with immunoprecipitates and the supernatant remains of the immunoprecipitates. Measurement of the total JAK2 present in the starting samples and tyrosine-phosphorylated JAK2 or SOCS3-associated JAK2 were obtained from the densitometric analyses of samples. There was no variation in JAK2 expression after Ang II treatment; however, tyrosine-phosphorylated JAK2 peaked at 10 min and corresponded to 10% of the total JAK2. SOCS3-associated JAK2 was higher at 60 min and corresponded to 15% of the total JAK2 (Fig. 4, A  and B) . 
Abrogation of Ang II desensitization by the blockade of SOCS3 expression with antisense oligonucleotide
Ang II induces the expression of early inducible genes such as c-fos, c-jun, c-myc, and egr-1 in cultured cells and animals (2, 29) . Repeated exposure to Ang II leads to a reduced induction of the expression of these genes and to refractoriness in several physiological phenomena modulated by Ang II (30, 31) . To test the hypothesis that the induction of SOCS3 by Ang II might be involved in mechanisms of refractoriness to Ang II signaling, we blocked the expression of SOCS3 with a sequence-specific phosphorthioate antisense oligonucleotide and evaluated the ability of repetitive doses of Ang II to induce the expression of c-Jun in heart and isolated cardiomyocytes. Initially, the ability of the antisense   FIG. 3 . Evaluation of SOCS3/JAK2 association and Ang II receptor type involved in Ang II-induced SOCS3 expression in heart and NRVM. A, The animals were anesthetized, the abdominal cavity was incised, and 0.02 ml 10 Ϫ6 M Ang II (AII) was infused through the vena cava. After the elapsed time indicated in the figure, the tips of the left ventricles were excised and homogenized in solubilization buffer, 5 mg protein were submitted to immunoprecipitation (IP) with anti-SOCS3 (␣ SOCS3) antibody, the immunoprecipitates were separated in 12% SDS-PAGE gels and transferred to nitrocellulose membranes, and the membranes were immunoblotted (IB) with anti-JAK2 (␣ JAK2) antibody. The inset depicts a whole blot of a typical run containing a sample from a control (0 min) and a sample from a 10 Ϫ6 M Ang II-treated rat (n ϭ 3; *, P Ͻ 0.05). B, Rats were anesthetized, the abdominal cavity was incised, and 0.02 ml 10 Ϫ6 M Ang II was infused through the vena cava. After 120 min, the tips of the left ventricles were excised and homogenized in solubilization buffer, 5.0 mg of protein was submitted to immunoprecipitation with anti-JAK2 antibody, the immunoprecipitates were separated in 12% SDS-PAGE gels and transferred to nitrocellulose membranes, and the membranes were immunoblotted with anti-SOCS3 antibody (n ϭ 3). C, NRVM were prepared following a technique described in the text and were plated in DMEM at a concentration of 6.0 ϫ 10 4 /cm 2 . Ang II was added to culture medium at the concentrations depicted in the figure, and after 120 min, cells were harvested, homogenized, and used for immunoprecipitation with anti-SOCS3 antibody. Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with anti-JAK2 antibody (n ϭ 3; *, P Ͻ 0.05). D-G, Living rats (D and F) or NRVM (E and G) were treated with losartan (L), Ang II (AII), or losartan followed by Ang II (L-AII); after 10 min (for IP: AT1, JAK2; IB with phospho-STAT1) or after 120 min (for IP, SOCS3), the tips of the left ventricles were excised and homogenized in solubilization buffer as described in the text (D and F), or cells were harvested and homogenized (E and G). Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antiphosphotyrosine antibodies (␣ pY) or anti-SOCS3 antibodies (␣ SOCS3). Total extracts were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antiphospho-STAT1 antibody (␣ p-STAT1). Depicted are representative examples of three different experiments. CTL, Control; MW, molecular mass standards in kilodaltons.
oligonucleotide to block Ang II-induced SOCS3 protein synthesis was evaluated by immunoblots of total protein extracts (Fig. 5, A and B) . Rats or cells were treated with sense, antisense, or scrambled SOCS3 oligonucleotides and, after the incubation time stated in the figure, were chased with Ang II (0.02 ml 10 Ϫ6 m for rats or 10 Ϫ7 m for cells). The optimal time for pretreatment with oligonucleotide was established as 3 h for rats and 8 h for cells. These preincubation times were employed in all experiments thereafter. One group of cardiomyocytes was exposed to Ang II plus neomycin to block protein synthesis. As depicted in Fig. 5 , C and D (lanes AII), treatment with Ang II without prior infusion of antisense oligonucleotides promoted a 4-to 5-fold increase in SOCS3 expression in heart and cardiomyocytes, respectively (after 120 min of Ang II treatment). Prior infusion of SOCS3 antisense oligonucleotide completely abolished Ang IIinduced SOCS3 expression. This expression was detected when only one dose of Ang II was injected (Fig. 5, C and D, lanes AII) or when two subsequent doses, separated by 120 min, were used (Fig. 5, C and D, lanes AS-AII-AII) . Pretreating rats with SOCS3 sense and scrambled oligonucleotides did not block Ang II-induced SOCS3 expression (Fig. 5A A single dose of Ang II (0.02 ml 10 Ϫ6 m in rats or 10 Ϫ7 m in NRVM) caused 4.5-and 3.5-fold increases in c-Jun protein expression in heart and NRVM, respectively, as detected by immunoblots of total protein extracts (Fig. 5 , E and F, lanes AII 120 min). If a second dose of Ang II was injected 120 min after the first dose, the rise in c-Jun expression was only 2.5-and 1.5-fold in heart and NRVM, respectively (Fig. 5, E and F, lanes AII-AII), which differed significantly from the amount of c-Jun before any Ang II stimulus or after a single dose of Ang II. The levels of c-Jun 240 min after a single dose of Ang II were almost undetectable (Fig. 5 , E and F, lanes AII 240 min). Thus, there was refractoriness to consecutive doses of Ang II, as shown by the ability of Ang II to stimulate an early inducible gene that participates in control of the expression of other genes induced by Ang II. Pretreating the rats with SOCS3 sense or antisense oligonucleotides did not induce c-Jun expression. However, the blockade of SOCS3 partially overcame the phenomenon of Ang II-induced refractoriness to the expression of c-Jun (Fig. 5, E and F, lanes AS-AII-AII). The level of c-Jun when animals were exposed to SOCS3 sense oligonucleotide and then to two consecutive doses of Ang II (interval of 120 min between doses) was similar to that observed when the two doses of Ang II were not preceded by oligonucleotide treatment (Fig. 5E , lane S-AII-AII). The blockade of AT1 with losartan reduced, but did not completely abolish, the property of Ang II to induce the expression of the protooncogene c-fos (Fig. 5E , lane L-AII), which is in agreement with previous findings (32, 33) .
JAK/STAT pathway-specific events are controlled by SOCS3
Different intracellular signaling pathways are activated in response to Ang II. To investigate the specificity of the signal transduction-blocking effect exerted by SOCS3 on signaling events induced by Ang II, rats were treated with one or two subsequent doses of Ang II, and the tyrosine phosphorylation of JAK2, STAT1, and ERK (which is activated by Ang II through a different pathway) was assessed. A single dose of A and B, The rats were anesthetized, the abdominal cavity was incised, and 0.02 ml 10 Ϫ6 M Ang II was infused through the vena cava. After the elapsed time indicated in the figure, the tips of the left ventricles were excised and homogenized in solubilization buffer, 0.25 mg protein was submitted to immunoprecipitation (IP) with 5.0 g antiphosphotyrosine antibody (␣ pY; A) or 5.0 g anti-SOCS3 antibody (␣ SOCS3; B). SDS-PAGEs were used to separate total products obtained from immunoprecipitations and the supernatants of the immunoprecipitation reactions; 0.25 mg total protein extracts from the same samples that were used for immunoprecipitations were separated by SDS-PAGE as well. All membranes were blotted in parallel using anti-JAK2 antibody (␣ JAK2) and incubated with 2.0 mCi [ 125 I]protein A, and bands were detected by autoradiography using preflashed Kodak XAR film with Cronex Lightning Plus intensifying screens at Ϫ70 C for 72 h. Band intensities were quantified by digital densitometry of the developed autoradiographs, and individual arbitrary densitometric units obtained for each band were used for calculating the relative amount of JAK2 in each sample. Depicted are representative examples of three different experiments. For this, rats were treated with saline or Ang II (10 Ϫ6 M) for 3, 10, 30, or 60 min. Hearts were excised and homogenized, and protein extracts were obtained. From each condition, two samples of 0.25 mg were obtained. One sample was used to run the total extract and was blotted with anti-JAK2 antibody; the second sample was used in IP experiments with the above antibodies. Both the protein obtained in the pellet of the immunoprecipitation and the protein remaining in the supernatant were integrally loaded onto SDS-PAGEs, separated, transferred to nitrocellulose membranes, and blotted with anti-JAK2 antibodies.
Ang II induced significant tyrosine phosphorylation of JAK2, STAT1, and ERK (Fig. 6, lane AII) . Two subsequent doses of Ang II led to a loss of effect, such that the tyrosine phosphorylation levels of JAK2, STAT1, and ERK did not differ significantly from basal (Fig. 6, lane AII-AII) . AT1 participation in these events was assessed by using losartan (10 mg/kg; Fig. 6 , lanes L and L-AII). The blockade of SOCS3 expression by the antisense oligonucleotide reversed the desensitizing action of Ang II on the tyrosine phosphorylation of JAK2 and STAT1, but not on the tyrosine phosphorylation of ERK (Fig. 6, AS-AII-AII) .
Discussion
Desensitization of Ang II signaling may be defined as attenuation of the response after repetitive injections of the hormone (30) and may provide a mechanism of protection against possible harmful effects imposed by overstimulation. Some of the pathways involved in Ang II signal regulation, mostly via AT1, have been characterized. Receptor internalization after ligand binding involves specific clustering of the receptors in clathrin-coated pits and depends on a signal sequence present in the proximal part of the cytoplasmic C-terminal tail of the receptor (34) . Serine/threonine phos- After 120 min, cells were harvested, homogenized, and submitted to procedures for detection of SOCS3 expression as described in Materials and Methods and below. Control groups were treated with sense (S) and scrambled (SC) oligonucleotides and with neomycin (Neo). Rats (C and E) were treated, or not, with 6.0 nmol (ip) phosphorthioate sense (S-AII-AII) or antisense (AS-AII-AII) oligonucleotide to SOCS3 3 h before beginning the experiments or received 1.0 ml losartan (ip, 10 mg/kg weight body; L and L-AII) 30 min before the beginning of experiments. Then they were anesthetized, the abdominal cavity was opened, and one (AII and L-AII) or two (AII-AII, S-AII-AII, and AS-AII-AII) consecutive doses of Ang II (0.02 ml 10 Ϫ6 M) were infused into the vena cava as a bolus injection. After 120 or 240 min (as depicted in figure) , the tip of the left ventricle was excised and homogenized in solubilization buffer at 4 C, and protein extracts were prepared and used as described below. NRVM (D and F) plated in DMEM at a concentration of 6.0 ϫ 10 4 /cm 2 were treated with losartan (L; 10 Ϫ5 M), Ang II (10 Ϫ7 M), and sense (S) or antisense (AS) SOCS3 oligonucleotides (1.0 M) as stated in the text. Cells were exposed to one of the following treatments: a single dose of Ang II (AII), two consecutive doses of Ang II (AII-AII), a single dose of losartan (L), losartan followed by Ang II (L-AII), SOCS3 sense oligonucleotide followed by two consecutive doses of Ang II (S-AII-AII), or SOCS3 antisense oligonucleotide followed by two doses of Ang II (AS-AII-AII). For c-Jun detection (E and F), 200 g protein were subjected to SDS-PAGE gels, transferred to nitrocellulose membranes, and blotted (IB) with anti c-Jun (␣ c-Jun) antibody. For SOCS3 detection (A-D), 5.0 mg protein were subjected to IP with rabbit anti-SOCS3 (␣ SOCS3) antibody, and immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes, and blotted (IB) with goat anti-SOCS3 antibody [n ϭ 3; *, P Ͻ 0.05 vs. control (CTL); #, P Ͻ 0.05 vs. CTL and AII; §, P Ͻ 0.05 vs. CTL and S-AII-AII]. E and F, Insets depict a whole blot of a typical run for heart (E) and NRVM (F) c-Jun detection. MW, Molecular mass standards in kilodaltons.
phorylation also participates in the control of signal transduction and leads to signal shutdown by promoting receptor-G protein uncoupling (35) . Another mechanism demonstrated in isolated cardiac fibroblasts involves a rapid (30-sec) and transient (30-min) desensitization through protein kinase C activation and leads to up to 50% reduction of Ca 2ϩ accumulation after subsequent exposure to Ang II (36) . Finally, the participation of the JAK/STAT signaling pathway in the transduction of Ang II signals appears to be controlled by the phosphatase Src homology protein tyrosine phosphatase 1 (SHP1), which binds to a complex formed by JAK2, SHP2, and AT1 and participates in receptor and kinase tyrosine dephosphorylation (37) .
Recently, members of the cytokine I and cytokine II receptor families were shown to induce, on a ligand receptor activation basis, the expression and functional activation of SOCS proteins. This new class of proteins, which currently includes eight members (11, 12) , is characterized by the possession of a highly conserved C-terminal domain, the SOCS box, a core Src homology 2 domain, and a variable Nterminal head (38) . SOCS proteins are induced through activation of the JAK/STAT pathway by several cytokines, leptin (39, 40) , insulin (41), GH (42, 43) , and PRL (44, 45) . When expressed, SOCSs inhibit the signaling and biological activities of the inducers (39, 45) . These findings suggest that SOCS proteins can function as inducible intracellular negative regulators of signal transduction.
As JAK2 and several STAT proteins are activated and participate in Ang II signal transduction, we examined whether SOCSs proteins are induced by Ang II in heart, and whether they participate in the control of Ang II signal transduction or ligand-induced desensitization. The choice to evaluate SOCS3 was based on the fact that other hormones, such as leptin, insulin, and GH, are already known to induce SOCS3 expression. As shown in Figs. 1 and 2 , SOCS3 is already expressed at low levels in heart and isolated cardiomyocytes, even before Ang II treatment. Based on the histological evaluation, most immunoreactive SOCS3 occurs in the endocardium and in vascular muscle wall and endothelial cells of the coronary arteries, whereas very faint staining is observed in cardiac muscle. SOCS3 mRNA is also present in nonstimulated heart. After the injection of a supraphysiological dose (10 Ϫ6 m) of Ang II, there is a rapid in vivo rise in the protein levels of SOCS3 (as early as 10 min), whereas a significant increase in mRNA levels occurs after 60 min. These facts suggest that both translational and transcriptional regulation of SOCS3 may be under Ang II control. Modulation of the rate of SOCS3 degradation may also favor protein accumulation. Treatment with Ang II increases SOCS3 expression, as shown by a higher intensity of staining (all figures were obtained using exactly the same protocol, and experiments were run in parallel), but causes no shift in the pattern of staining, i.e. higher expression is maintained in the endocardium and endothelium. As a high level of SOCS3 expression is observed in NRVM after treatment with Ang II, we suspect that due to differences in age (1-to 3-d-old rats for NRVM preparation and 48-d-old rats for the heart experiments), higher levels of AT1 in isolated cardiomyocytes might be responsible for the enhanced effect observed.
The intracava injection of at least 0.02 ml 10 Ϫ8 m Ang II significantly elevates the level of SOCS3 protein in heart homogenates. This quantity of Ang II provides a circulating concentration that approximates the stimulus-induced range of approximately 100 ng/liter (46) and suggests that stimulation of SOCS3 expression is a physiological phenomenon that may modulate Ang II function. This conclusion is further supported by the ability to induce SOCS3 with 10 Ϫ7 m Ang II in isolated cardiomyocytes. To test the hypothesis of a physiological role for Ang II-induced SOCS3 expression, we used SOCS3-specific phosphorthioate-modified antisense oligonucleotide to block SOCS3 expression and evaluated the ability of repeated doses of Ang II to induce the expression of the early inducible gene c-jun. After a single dose of Ang II, the expression of c-Jun rapidly increases by up to 5-fold above basal levels after 120 min. After a second dose of Ang II, injected 120 min after the first dose, the increase is only 2.5-and 1.5-fold above basal in heart and NRVM, respectively. These results indicate that desensitization to stimulation by Ang II occurs in both systems tested. In rats pretreated with SOCS3 antisense oligonucleotide, a second dose of Ang II produces an increase of about 3.8-fold above basal, which is significantly different from the responses to single and double doses of Ang II in nonpretreated rats. These results indicate that SOCS3 participates in the control of Ang IIinduced c-Jun expression, although this is not the only mechanism involved in the control of signal transduction by this path. The experiments with losartan indicate that Ang II induces SOCS3 only through AT1 receptors, whereas c-Jun may be induced by the activation of both AT1 and AT2 receptors. This fact may explain why in the absence of FIG. 6 . Effects of losartan and SOCS3 antisense oligonucleotide treatment on activation of the JAK2/STAT1 and ERK signaling pathways. Rats were treated, or not, with 6.0 nmol (ip) phosphorthioate sense (S-AII-AII) or antisense (AS-AII-AII) oligonucleotide to SOCS3 3 h before beginning the experiments or received 1.0 ml losartan (ip, 10 mg/kg weight body; L and L-AII) 30 min before beginning the experiments. Then they were anesthetized, the abdominal cavity was opened, and one (AII and L-AII) or two (AII-AII, S-AII-AII, and AS-AII-AII) consecutive doses (interval of 120 min between doses) of Ang II (0.02 ml 10 Ϫ6 M) were infused into the vena cava as a bolus injection. After 5 min, the tip of the left ventricle was excised and homogenized in solubilization buffer at 4 C, and protein extracts were prepared; 5.0 mg protein were submitted to immunoprecipitation (IP) with anti-JAK2 (␣ JAK2) antibody, the immunoprecipitates were separated by SDS-PAGE and transferred to nitrocellulose membranes, the membranes were immunoblotted (IB) with antiphosphotyrosine (␣ pY) antibody, or 0. SOCS3, the expression of c-Jun after the second dose of Ang II did not reach the same levels as those observed with a single dose of Ang II, as other mechanisms controlling AT2-induced c-Jun expression would still be operating in the presence of SOCS3 blockade.
In a parallel series of experiments not described here, Ang II-induced expression of SOCS3 was examined in the hypothalamus, another important site of Ang II action. In this tissue, SOCS3 was induced in the anterodorsal preoptic nucleus and median preoptic lateral nucleus by the intracerebroventricular injection of Ang II and was found to participate in the control of water balance (Torsoni, M. A., and L. A. Velloso, unpublished data).
As a final objective of the present study, we evaluated the specificity of the blocking effect of SOCS3 toward the JAK/ STAT signaling pathway. Immunodepletion experiments showed that 10 -15% of the JAK2 pool expressed in the target tissue is involved in Ang II signaling, as evaluated by the tyrosine phosphorylation of JAK2 and the association of JAK2 with SOCS3. In other signaling systems that use JAK2 as an intermediary signaling molecule, the extent of this involvement is also about 10 -20% of all JAK2 available (47, 48) . In rats treated with antisense oligonucleotide, two doses of Ang II caused desensitization of the signaling response involving ERK, but not JAK2 and STAT1. As SOCS3 is believed to hamper specific signaling occurring through JAK family members (49) , and as Ang II activates ERK through a JAK2-independent mechanism (8), the maintenance of molecular desensitization of Ang II-induced ERK activation after partial abrogation of SOCS3 expression would be predictable.
In conclusion, this is the first evidence for the participation of a protein belonging to the SOCS family in the control of physiological actions of Ang II. This is also the first demonstration of the induction of a SOCS protein through a G protein-coupled receptor. These findings provide a new field of investigation into the mechanisms controlling Ang II signal transduction and reinforce the concept that in several ways Ang II acts as a cytokine.
